ENvue Medical

Company Overview

Snapshot

Founded in December 2003, ENvue Medical operates with 11–50 employees and has raised a total of $24.5M across nine funding rounds. The company went public on NASDAQ in April 2014, marking a significant milestone in its journey to redefine clinical navigation.

Business overview

ENvue Medical develops technology for clinical navigation, focusing on enhancing critical procedures such as enteral feeding and vascular access. Its Enhanced Navigation platform aims to reduce complications, accelerate training, and improve efficiency in healthcare settings. The company serves hospitals and clinicians, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In May 2026, ENvue Medical secured a three-year purchasing agreement renewal with a Group Purchasing Organization (GPO) representing one of the largest health systems in the U.S., operating over 90 hospitals. This renewal, alongside another three-year contract renewal at a 12-hospital U.S. health network, signals strong market adoption and validation of the ENvue™ Navigation Platform, indicating its increasing role as a standard of care and a positive trajectory for the company's commercial growth.

Company Intelligence Q&A

What was a key development for ENvue Medical's intellectual property in May 2026?

In May 2026, ENvue Medical added to its intellectual property portfolio by securing a USPTO Notice of Allowance for its Ultrasound-Enhanced Cannabinoid Drug Delivery Technology.

What significant commercial agreement did ENvue Medical secure in May 2026?

In May 2026, ENvue Medical secured a three-year purchasing agreement renewal with a Group Purchasing Organization (GPO) for one of the largest health systems in the U.S., operating over 90 hospitals. Additionally, the ENvue™ Navigation Platform became the standard of care at a 12-hospital U.S. health network following a three-year contract renewal.

What strategic acquisition did ENvue Medical complete in February 2025?

In February 2025, ENvue Medical acquired Envizion Medical, expanding its capabilities and market presence.

What was a notable product adoption milestone for ENvue Medical in May 2025?

In May 2025, a major Louisiana hospital selected the ENvue System for its feeding tube procedures, indicating growing adoption of the company's technology.

What was the outcome of NanoVibronix's registered direct offering in September 2025?

In September 2025, NanoVibronix announced the pricing of a $2.0 million registered direct offering, priced at-the-market under Nasdaq rules.